Dose: 0.114 to 0.228 mg/kg
Single Dose: 0.17 (0.171)
Frequency: 24 hourly
Route: PO
Instructions: -

Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group

Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group

Perphenazine Enantate is the derivative of Perphenazine. It is of Synthetic origin and belongs to Phenothiazine. It belongs to D2 antagonist pharmacological group on the basis of mechanism of action and also classified in Psychotherapeutic Drugs pharmacological group.The Molecular Weight of Perphenazine is 404.00. Its pKa is 7.8.

Perphenazine is contraindicated in conditions like Blood dyscrasias,Bone marrow depression,Coma,Brain damage,Pregnancy,Subcortical brain damage,Breast feeding,Hypersensitivity to any component of product.

The severe or irreversible adverse effects of Perphenazine, which give rise to further complications include Tachycardia, Cardiac arrhythmias, Urticaria, Hypotension, Jaundice, Extrapyramidal symptoms, Numbness, Gynacomastia, Dystonia, Slurred speech, Trismus, Retrocollis, Motor restlessness, Aching, Hyperreflexia, Anaemia.Perphenazine produces potentially life-threatening effects which include Coma, Neuroleptic Malignant Syndrome, Stupor, Extrapyrimidal symptoms. which are responsible for the discontinuation of Perphenazine therapy.The signs and symptoms that are produced after the acute overdosage of Perphenazine include Hypotension, Tachycardia, Confusion, Hypotonia, Hypothermia, Miosis, Tremor, Restlessness.The symptomatic adverse reactions produced by Perphenazine are more or less tolerable and if they become severe, they can be treated symptomatically, these include Constipation, Dry mouth, Blurred vision, Pain, Sedation, Miosis, Mydriasis.

Perphenazine is primarily indicated in conditions like Bipolar disorders, Mania, Nausea and vomiting, Psychosis, Schizophrenia, and can also be given in adjunctive therapy as an alternative drug of choice in Post-operative nausea and vomiting.

Perphenazine is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAlcoholAtropine (Sulphate)Clonidine (HCl)GuanethidineImipramine (HCl)LevodopaMethyldopaNalidixic AcidPethidine (HCl)Phenytoin (Na) These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

False +ve tst for urobilinogen, amylase, uroporphyrins, porphobilinogens Abnormal LFTs

Drug should not be given to Paediatrics, Pregnant Mothers, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Inj Store Below 40°C. Do not Freeze. Protect from Sunlight and Moisture. Tab Store Below 40°C. Protect from Sunlight and Moisture.

Perphenazin should be used with caution or not at all in patients with impaired liver, kidney, cardiovascular, cerebrovascular, and respiratory function and in those with angle-closure glaucoma, a history of jaundice, parkinsonism, diabetes mellitus, hypothyroidism, myasthenia gravis, paralytic ileus, prostatic hyperplasia, or urinary retention. Care is required in patients with epilepsy or a history of seizures. Regular eye examinations are advisable for patients receiving long-term Perphenazine Enantate and avoidance of undue exposure to direct sunlight is recommended. Should be used with caution in the presence of acute infection or leucopenia. Blood counts are advised if the patient develops an unexplained infection or fever. Generally not recommended late in pregnancy; such use may be associated with intoxication of the neonate. Photosensitization may occur, caution patients against exposure to sunlight or UV light. Discontinue use at least 48 hrs. before myelography.